This site is intended for healthcare professionals
Guidelines
  • Home
  • /
  • Guidelines
  • /
  • Non-Hodgkin lymphoma
  • /
  • Waldenström's macroglobulinaemia: ESMO Clinical Pr...
Guideline

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Read time: 1 mins
Last updated:1st Oct 2018
Waldenström’s macroglobulinaemia: European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for diagnosis, treatment and follow-up


The 2018 ESMO Clinical Practice Guidelines on Waldenström’s Macroglobulinemia (WM) are based on results from recent studies and updated analyses. New recommendations are given regarding the role of MYD88 L265P detection in the diagnosis of WM and the role of ibrutinib in the treatment of symptomatic WM. Updated recommendations on patient-specific and symptom-based treatment selection are given.

 

Read full guideline